HUMA
Humacyte, Inc.Company Information
- Company Name
- Humacyte, Inc.
- CIK
- CIK0001818382
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- HUMA: Nasdaq, HUMAW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- HUMA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-14
- Last sale
- 2026-05-18
- Shares purchased (TTM)
- 117,818
- Shares sold (TTM)
- 91,774
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 71,570,696
- Shares outstanding
- 234,182,284
- Ownership
- 30.56%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -9.02%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 80 | 49 | 50 | 19 | 38 | 63 | 45 | 21 | 94 | 116 | 80 | 100 | ||||||
| Inventory Net | 7 | 10 | 14 | 18 | 11 | 8 | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 1 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 5 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 3 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 93 | 64 | 68 | 41 | 52 | 74 | 48 | 23 | 96 | 118 | 83 | 103 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 50 | 50 | 50 | 50 | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 16 | 17 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | ||||||
| Finance Lease Right Of Use Asset | 28 | 29 | 29 | 29 | 14 | 15 | 15 | 16 | 17 | 17 | 17 | 18 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 138 | 111 | 116 | 92 | 139 | 163 | 138 | 115 | 138 | 161 | 128 | 149 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 5 | 10 | 7 | 6 | 4 | 7 | 6 | 3 | 6 | 3 | ||||||
| Accrued Liabilities Current | 9 | 9 | 11 | 10 | 9 | 10 | 11 | 11 | 9 | 8 | 9 | 10 | ||||||
| Finance Lease Liability Current | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Unsecured Debt Current | - | - | 0 | 3 | 2 | 2 | 1 | - | - | - | - | - | ||||||
| Other Liabilities Current | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Liabilities Current | 15 | 16 | 18 | 26 | 21 | 20 | 20 | 21 | 18 | 14 | 18 | 15 | ||||||
| Unsecured Long Term Debt | - | - | - | 18 | 66 | 65 | 63 | 62 | 60 | 58 | 39 | 37 | ||||||
| Long Term Debt | 36 | 36 | 35 | - | - | - | 0 | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 9 | 7 | 11 | 22 | 27 | 21 | 71 | 77 | 68 | 43 | 38 | 40 | ||||||
| Secured Debt Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Warrants And Rights Outstanding | 16 | 11 | 19 | 3 | 4 | 3 | 19 | - | - | - | 0 | - | ||||||
| Finance Lease Liability Noncurrent | 28 | 28 | 27 | 27 | 12 | 13 | 14 | 14 | 15 | 16 | 16 | 17 | ||||||
| Derivative Liabilities Noncurrent | - | - | 0 | 0 | 3 | 3 | 2 | 3 | 4 | 4 | 3 | 3 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 107 | 99 | 113 | 96 | 135 | 127 | 191 | 178 | 167 | 135 | 115 | 112 | ||||||
| Secured Long Term Debt | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 813 | 756 | 730 | 697 | 689 | 683 | 633 | 601 | 598 | 595 | 551 | 549 | ||||||
| Retained Earnings Accumulated Deficit | -781 | -744 | -727 | -702 | -685 | -647 | -686 | -665 | -626 | -569 | -537 | -512 | ||||||
| Stockholders Equity | 31 | 12 | 3 | -5 | 4 | 36 | -53 | -64 | -28 | 26 | 14 | 37 | ||||||
| Liabilities And Stockholders Equity | 138 | 111 | 116 | 92 | 139 | 163 | 138 | 115 | 138 | 161 | 128 | 149 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 278 | 222 | 193 | 159 | 156 | 155 | 130 | 120 | 119 | 119 | 104 | 103 | ||||||
| Shares Outstanding | 278 | 222 | 193 | 159 | 156 | 155 | 130 | 120 | 119 | 119 | 104 | 103 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHumacyte, Inc. (HUMA) — SEC Financial Statements & Analysis
Humacyte, Inc. (HUMA) is a biological products, (no diagnostic substances) company, incorporated in DE. Humacyte, Inc. trades on Nasdaq as: HUMA, HUMAW. Humacyte, Inc. (HUMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Humacyte, Inc. carries a market cap of $182.66M, a P/E ratio of -1.89x, a P/B ratio of 5.84x, a P/S ratio of 86.12x, an enterprise value of $138.73M, and an EV/EBITDA multiple of -1.31x. On profitability, it posts a gross margin of -494.58%, an operating margin of -5240.78%, a net margin of -4560.82%, a Return on Equity (ROE) of -547.87%, and a Return on Assets (ROA) of -69.87%. Per share, it reports EPS of $-0.41, diluted EPS of $-0.41, free cash flow per share of $-0.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 159.29% year-over-year, net income growth of 64.91% year-over-year, and EPS growth of 9.45% year-over-year. On the balance sheet, it maintains a current ratio of 6.21x, a quick ratio of 5.37x, working capital of $77.84M, a debt-to-equity ratio of 3.42x, a debt ratio of 0.77, an interest coverage ratio of -10.80x, free cash flow of $-97.56M (TTM), and net debt of $-43.93M. Figures sourced from SEC EDGAR.
- Market Cap
- $182.66M
- P/E TTM
- -1.89x
- EPS TTM
- $-0.41
- P/B TTM
- 5.84x
- ROE TTM
- -547.87%
- ROA TTM
- -69.87%
- Debt To Equity
- 3.42x
- Free Cash Flow TTM
- $-97.56M
- Net Revenue TTM Growth 1Y
- 159.29%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Humacyte, Inc. in?
Humacyte, Inc. (HUMA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does HUMA trade on?
Humacyte, Inc. (HUMA) trades on the Nasdaq.
Where is Humacyte, Inc. incorporated?
Humacyte, Inc. is incorporated in DE.
When was Humacyte, Inc. (HUMA)'s most recent SEC filing?
Humacyte, Inc. (HUMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is HUMA's market cap?
Humacyte, Inc. (HUMA) has a market capitalization of $182.66M as of 2026-06-30.
What is HUMA's EPS (earnings per share)?
Humacyte, Inc. (HUMA)'s trailing twelve month EPS is $-0.41 as of 2026-06-30.
What is HUMA's ROE (return on equity)?
Humacyte, Inc. (HUMA)'s trailing twelve month Return on Equity (ROE) is -547.87% as of 2026-06-30.
What is HUMA's ROA (return on assets)?
Humacyte, Inc. (HUMA)'s trailing twelve month Return on Assets (ROA) is -69.87% as of 2026-06-30.
What is HUMA's EV/EBITDA?
Humacyte, Inc. (HUMA)'s trailing twelve month EV/EBITDA is -1.31x as of 2026-06-30.